Modeling of annual treatment costs and health outcomes of antipsychotic agents for schizophrenic populations. Based on a presentation by Josephine Mauskopf, PhD.
Schizophrenia is associated with the extensive use of inpatient services, so the costs of treating it are substantial. As a result, a treatment that can reduce the symptoms leading to inpatient care may decrease the overall costs and increase the quality of life for patients, their families, and society. Today, healthcare planners are faced with the delicate balancing act of providing the best care possible within limited budgets. A risk in budget assessment is looking at line items individually rather than at the total healthcare costs and clinical outcomes. For example, a drug may increase pharmacy budgets but lower inpatient services use or increase employment. A population model is described that can be used to predict the impact of new agents, such as atypical antipsychotics, and help decision makers plan budgets and revise current treatment strategies accordingly. Population models enable planners to plug in the cost and incidence numbers for their patient population and examine the total cost and patient outcomes. Such models provide a bigger picture of disease state management within a given setting.
D014150:Antipsychotic Agents / Q000191:economics* / Q000627:therapeutic use; D002017:Budgets; D017281:Cost of Illness; D019468:Disease Management; D006302:Health Services Research; D006801:Humans; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000145:classification / Q000188:drug therapy* / Q000191:economics*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States
D014150:Antipsychotic Agents